Hyderabad-based Indian Immunologicals Limited (IIL) has partnered with Australia’s Griffith University to develop the COVID-19 vaccine. Scientists from IIL and Griffith University will jointly develop a “live attenuated SARS – CoV-2 vaccine” or COVID-19 vaccine using the “latest codon de-optimization technology”.
The vaccine is expected to provide long-lasting protection with a single dose administration with an anticipated safety profile similar to other licensed vaccines for active immunization. Upon the completion of the research, the vaccine strain will be transferred to ILL. It will work with the Central Drugs Standard Control Organisation (CDSCO), to conduct clinical trials. IIL intends to use its Vero cell platform tech for mass production of the vaccine.
What is Indian Immunologicals Limited?
Indian Immunologicals Limited is a major player in the human vaccine market in the country, supplying human pediatric and rabies vaccines. IIL is also a major supplier of pediatric vaccines to the country’s state-run universal immunization programme. IIL is promoted by the National Dairy Development Board. It is committed to addressing critical public health needs by engaging in this collaboration.
Important takeaways for all competitive exams:
- Headquarters of Indian Immunologicals Limited (IIL): Hyderabad, Telangana.
- Indian Immunologicals Limited (IIL) founded: 1982.
- Chairman of Indian Immunologicals Limited (IIL): Dilip Rath.